Eddie Garon, UCLA, reviews the controversial question of whether
PD-L1 expression is a reliable enough biomarker to be used to
select patients to receive or not receive immune checkpoint
inhibitor therapy in lung cancer.
About the Podcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.